Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernardo P Marson

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinica Chimica Acta; International Journal of Clinical Chemistry|January 31, 2008
eNOS polymorphisms in hypertensionBernardo P Marson
Basic & Clinical Pharmacology & Toxicology|February 9, 2012
Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological targetBernardo P Marson, Carlos E Poli de Figueiredo, Jose E Tanus-Santos
American Journal of Nephrology|February 4, 2012
Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney diseaseBernardo P Marson, Riccardo Lacchini, Vanessa Belo, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|September 27, 2012
Functional matrix metalloproteinase (MMP)-9 genetic variants modify the effects of hemodialysis on circulating MMP-9 levelsBernardo P Marson, Riccardo Lacchini, Vanessa Belo, et al.
DNA and Cell Biology|September 21, 2010
Endothelial nitric oxide genotypes and haplotypes are not associated with end-stage renal diseaseBernardo P Marson, Samantha Dickel, Marília H Ishizawa, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinica Chimica Acta; International Journal of Clinical Chemistry|January 31, 2008
eNOS polymorphisms in hypertensionBernardo P Marson
Basic & Clinical Pharmacology & Toxicology|February 9, 2012
Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological targetBernardo P Marson, Carlos E Poli de Figueiredo, Jose E Tanus-Santos
American Journal of Nephrology|February 4, 2012
Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney diseaseBernardo P Marson, Riccardo Lacchini, Vanessa Belo, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|September 27, 2012
Functional matrix metalloproteinase (MMP)-9 genetic variants modify the effects of hemodialysis on circulating MMP-9 levelsBernardo P Marson, Riccardo Lacchini, Vanessa Belo, et al.
DNA and Cell Biology|September 21, 2010
Endothelial nitric oxide genotypes and haplotypes are not associated with end-stage renal diseaseBernardo P Marson, Samantha Dickel, Marília H Ishizawa, et al.
Pageof 1